Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,360 | 2 | 99.8% |
| Education | $19.81 | 1 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $8,360 | 2 | $0 (2022) |
| Merck Sharp & Dohme LLC | $19.81 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $19.81 | 1 | Merck Sharp & Dohme LLC ($19.81) |
| 2022 | $8,360 | 2 | Regeneron Pharmaceuticals, Inc. ($8,360) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2023 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $19.81 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/14/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $4,179.91 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
| 07/14/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $4,179.91 | Research |
| Study: REGN1979-CLINICAL DEVELOPMENT PROGRAM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| REGN1979-CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $8,360 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 268 | 1,128 | $378,878 | $95,605 |
| 2022 | 6 | 293 | 1,158 | $388,961 | $97,672 |
| 2021 | 5 | 239 | 1,015 | $336,279 | $87,478 |
| 2020 | 6 | 224 | 805 | $191,694 | $61,694 |
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 156 | 762 | $248,412 | $59,585 | 24.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 254 | $85,090 | $24,611 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 32 | 69 | $33,189 | $8,266 | 24.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 20 | 30 | $7,650 | $1,872 | 24.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 12 | 13 | $4,537 | $1,270 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 144 | 695 | $226,364 | $55,446 | 24.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 73 | 352 | $117,920 | $30,520 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 21 | 40 | $18,899 | $5,017 | 26.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 23 | 27 | $9,423 | $2,446 | 26.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 13 | $8,450 | $2,197 | 26.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 21 | 31 | $7,905 | $2,046 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 121 | 574 | $186,266 | $47,293 | 25.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 65 | 377 | $126,295 | $33,782 | 26.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 24 | $11,544 | $3,118 | 27.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 19 | 21 | $7,329 | $1,977 | 27.0% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 16 | 19 | $4,845 | $1,307 | 27.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 60 | 347 | $119,021 | $31,296 | 26.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 107 | 399 | $60,760 | $25,584 | 42.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 17 | 18 | $3,204 | $1,659 | 51.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $1,920 | $1,521 | 79.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 16 | $4,592 | $1,057 | 23.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 13 | 13 | $2,197 | $578.20 | 26.3% |
About Dr. Matthew Weinstock, M.D
Dr. Matthew Weinstock, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2010. The National Provider Identifier (NPI) number assigned to this provider is 1982924833.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Weinstock, M.D has received a total of $8,380 in payments from pharmaceutical and medical device companies, with $19.81 received in 2023. These payments were reported across 3 transactions from 2 companies. The most common payment nature is "" ($8,360).
As a Medicare-enrolled provider, Weinstock has provided services to 1,024 Medicare beneficiaries, totaling 4,106 services with total Medicare billing of $342,448. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 06/02/2010
- Last Updated 03/27/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982924833
Products in Payments
- PREVYMIS (Drug) $19.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795